Based on the available data and the recent FDA approval, the panel consensus was to include pembrolizumab as a first-line chemotherapy for patients who are cisplatin-ineligible with locally advanced or metastatic disease. Pembrolizumab was added as a category 2A option for the following settings:

- Bladder Cancer
- Upper GU Tract Tumors: Renal Pelvis
- Upper GU Tract Tumors: Urothelial carcinoma of the ureter
- Urothelial Carcinoma of the Prostate
- Primary Carcinoma of the Urethra (urothelial carcinomas only)

See Submission for references.